25 AUGUST 2013, VOL. 2, NO. 2

   


25 AUGUST 2013, VOL. 2, NO. 2, PAGES 37-44.




About the Cover:  It has been more than ten years since the discovery of the SR/CR “super mouse”, and many significant advances have been made, particularly with regard to the ongoing clinical trials of the Leukocyte Infusion Therapy which originated from this “super mouse”. GRANULOCYTE THERAPY FOR CANCER is the first book ever published dealing with the origin and development of the Granulocyte Therapy for Cancer. (See page 43).




Table of Contents

EDITORS

The list of the Editors is updated every two issues. Only PDF is available.

Science Insights 2013, 2(2): 37-38.

» PDF


NEWS

Worldwide break news are selected.

Ghost Glaciers in Greenland (Burlington, USA)

How Can the Kids Learn Today? (Washington DC, USA)

Person-to-Person H7N9 Transmission (London, UK)

New Mayan Frieze (Guatemala City, GUATEMALA)

Stressful Moms (Ramat Gan, ISRAEL)

Oxytocin: The Love Hormone (Chicago, USA)

How Long Can We Live? (Frasquia, BOLIVIA)

Science Insights 2013; 2(2): 39-40.

» Full Text   » PDF


EDITOR'S CHOICE

Recent representative literatures are highlighted.

ANTHROPOLOGY: Social Monogamy in Primates

HEALTH: The State of US Health

GENETICS: Female-Specific Hypertension Loci

Science Insights 2013; 2(2): 41.

» Full Text   » PDF


PICTURE STATION

Moscow Landscape (1938, From Russia)

By Tatyana Mavrina

Science Insights 2013; 2(2): 42.

» Full Text    » PDF


BOOK REVIEW

Granulocyte Therapy for Cancer

By Wenying Wang, Dong Wang

Science Insights 2013; 2(2): 43-44.

» Full Text    » PDF

SUMMARY GRANULOCYTE THERAPY FOR CANCER is the first book ever published dealing with the origin and development of the Granulocyte Therapy for Cancer. Dr. Zheng Cui has been regarded as “the father of cancer resistance super-mice”, made great contribution to the progress of Cancer Immunology and Immunotherapy. This book, based on his ten years’ research, intends to present a comprehensive overview from the serendipity discovery of the cancer complete resistant/ spontaneous regression (CR/SR) mice to the relevant cancer target killing mechanism mediated by leukocytes, as well as how the innovative therapeutic approach, Leukocyte Infusion Therapy (LIFT) applicable to human cancer.